| 代码 名称 | 现价 | 涨跌 涨幅↓ | | --- | --- | --- | | 300255 常山药业 | 13.78 | +2.30 +20.03% | | 300363 博腾股份 | 29.64 | +4.18 +16.42% | | 002038 双鹭药业 | 11.74 | +1.07 +10.03% | | 000813 德展健康 | 4.54 | +0.41 +9.93% | | 688166 博瑞医药 | 29.39 | +2.29 +8.45% | | 688076 诺泰牛物 | 39.66 | +2.97 +8.09% | | 301393 吴帆生物 | 78.79 | +4.59 +6.19% | | 600721 百花医药 | 8.47 | +0.47 +5.88% | | 605116 奥锐特 | 23.01 | +1.20 +5.50% | | 301092 争光股份 | 32.62 | +1.24 =+1.95% | 自9月8日以来，医药各细分板块进入稳步上行阶段，其中涨幅最大的减肥药板块，14个交易日内涨超 22%。 今日，医药板块情绪格外高涨。 A股方面，CRO概念 ...

泰格医药营收同比下降超10%，归母净利润、扣非净利润分别下滑79.99%、42.13%，均创下历史最大跌 幅。主因临床订单价格战挤压利润空间，临床试验技术服务板块的毛利率从38.21%降至29.56%，降幅 高达8.65个百分点。同时 ，公司持有的君实生物、信达生物等Biotech股权二级市场估值缩水导致全年 非经常性损益亏损4.5亿元。 博腾股份更是由盈转亏，历史首次出现年度亏损，当期归母净利润、扣非净利润分别为-2.88亿 元、-2.72亿元。由于博腾股份九成收入来自小分子业务，在新兴赛道布局滞后，因而成为利润下滑幅 度最大的厂商之一。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 2024年，CXO赛道企业业绩显著承压，20家CXO企业实现营业收入870亿元，同比下滑4.3%；归母净利 润133.3亿元，同比下降23.9%；扣非净利润132.4亿元，降幅20.1%。从企业角度看，药明康德、康龙化 成、泰格医药、凯莱英、博腾股份五大头部企业净利润全线下滑。 其中，药明康德营收、净利润分别同比下滑2.73%、1.37%，历史首次出现营收、利润双降；康龙化成 归母净利润虽同比增长1 ...

Investment Rating - The report does not explicitly provide an investment rating for the China drug industry but discusses potential impacts of US drug pricing changes on the sector [5]. Core Insights - The report highlights significant uncertainty regarding the Trump administration's plans for US drug pricing, which could affect the Chinese drug industry in various ways [5]. - Changes in US drug pricing could hinder the Chinese drug industry's international expansion due to a perceived smaller US market, but may also create opportunities for Chinese innovative drugs to be licensed out due to R&D cost advantages [5]. - The report notes that Chinese CRO/CDMO companies may face mixed impacts; reduced R&D expenses from US clients could negatively affect them, while increased outsourcing demand could arise as companies seek cost-saving measures [5]. Summary by Sections Impact of US Drug Pricing Changes - The report discusses the uncertainty surrounding the implementation of a "most favored nation" pricing model and its potential opposition in the US [5]. - It emphasizes that the actual impact on the Chinese drug industry remains unclear due to various factors, including whether Medicare or Medicaid pricing will be affected [5]. Opportunities and Challenges for Chinese Companies - If US drug prices decrease, it could limit the Chinese drug industry's ability to expand internationally [5]. - Conversely, innovative drugs from China may have better licensing opportunities due to their potential R&D cost and speed advantages [5]. - For Chinese CRO/CDMO companies, the report suggests that while some clients may cut R&D expenses, the overall demand for outsourcing could increase [5].

Investment Rating - The industry investment rating is optimistic [1] Core Viewpoints - The report indicates that the turning point for the CXO sector has emerged, suggesting a positive outlook for investment [6][70] - The report highlights that domestic performance, orders, and AI are the main themes driving growth [5] - The report emphasizes the recovery of revenue growth year-over-year (YOY) and the gradual improvement in profitability [5][29] Summary by Sections Price Review - The medical research outsourcing index increased by 0.82% from December 31, 2024, to April 30, 2025, outperforming the pharmaceutical and biotechnology index by 0.64 percentage points [5] Financial Analysis - Revenue growth is showing a positive trend, with the average YOY revenue growth for CXO companies reaching 8.2% in Q1 2025 [28] - The average gross margin for Q1 2025 is 30.9%, reflecting a YOY increase of 1.1 percentage points [34] - The average net profit margin excluding non-recurring items is 8.0%, up by 12.5 percentage points YOY [34] Growth Potential - The report notes that the global healthcare industry is seeing a stabilization in private equity and venture capital financing, which is expected to drive demand recovery [6] - The report mentions that the order growth for leading companies remains strong, with notable increases in new orders for companies like Kailaiying and Kanglonghua [61] Operational Efficiency - Inventory turnover rates have improved, with an average of 3.36 in 2024, indicating a stabilization in operational efficiency [39] - The report anticipates that operational efficiency will continue to improve as leading CXO companies execute orders and enhance capacity utilization [39] Investment Strategy - The report recommends actively allocating investments in the CXO sector, particularly in small molecule and large molecule CDMO opportunities, as well as clinical CROs supported by domestic innovation policies [72]

Group 1 - The core viewpoint of the article highlights that Tigermed's stock closed at 43.77 yuan, down 1.04%, with a rolling PE ratio of 112.83 times, and a total market capitalization of 37.859 billion yuan [1] - The average PE ratio for the medical services industry is 37.79 times, with a median of 38.85 times, placing Tigermed at the 42nd position in the industry ranking [1] - As of the first quarter of 2025, 80 institutions hold shares in Tigermed, including 78 funds, 1 social security fund, and 1 other entity, with a total shareholding of 170.6648 million shares valued at 8.671 billion yuan [1] Group 2 - Tigermed's main business is providing comprehensive clinical research solutions as a Contract Research Organization (CRO) for new drug development, serving global pharmaceutical and medical device innovation companies [1] - The latest financial results for the first quarter of 2025 show that the company achieved operating revenue of 1.564 billion yuan, a year-on-year decrease of 5.79%, and a net profit of 165 million yuan, down 29.61% year-on-year, with a gross profit margin of 30.03% [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） 海外監管公告 本 公 告 乃 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）根 據 香 港 聯 合 交 易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 深 圳 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 杭州泰格醫藥科技股份有限公司 董事長 葉小平 香 港，2025年5月15日 於 本 公 告 日 期，執 行 董 事 為 葉 小 平 博 士、曹 曉 春 女 士、吳 灝 先 生 及 聞 增 玉 先 生；獨 立 非 執 行 董 事 ...

证券代码：300347 证券简称：泰格医药 公告编码（2025）026 号 杭州泰格医药科技股份有限公司 关于持股 5%以上股东新增质押及部分股份回购并解除质押的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下简称"公司"）近日接到公司持股5%以上股东曹 晓春女士通知，获悉曹晓春女士办理其持有的部分股份被质押以及部分股份回购并解除质 押业务，具体内容如下： 一、 质押变动的基本情况 | 股东名 | 是否为控 股股东或 | 本次质押 | 占其所 | 占公司 | 是否为 | 是否为 | 质押起始 | 质押到期 | 质权人 | 质押用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 称 | 第一大股 | 数量 | 持股份 | 总股本 | 限售股 | 补充质 | 日 | 日 | | | | | 东及其一 | （股） | 比例 | 比例 | | 押 | | | | | | | 致行动人 | | | | | | | | | | ...

Core Viewpoint - The domestic pharmaceutical industry is experiencing a slowdown in investment and financing, leading to a gradual decline in market demand growth, which is impacting the CXO sector, resulting in intensified competition and challenges for development [1] Summary by Category Industry Overview - In Q1 2025, among 29 listed CXO companies, five, including WuXi AppTec and Kanglong Chemical, reported revenues exceeding 1 billion yuan, indicating a mixed performance across the sector [1][2] - 17 companies achieved year-on-year revenue growth, while 12 companies saw declines ranging from 0.6% to 40.32% [1] Financial Performance - WuXi AppTec led the sector with a net profit of 3.672 billion yuan, followed by Kailai Ying and Kanglong Chemical with approximately 300 million yuan each; however, eight companies, including Nanmo Bio and Boteng Co., reported losses [1][2] - Year-on-year, 18 companies saw net profit growth, while 11 experienced declines, with the largest drop reaching 431.11% [1] Market Dynamics - The international business is becoming a focal point for domestic CXO companies, with WuXi AppTec reporting 6.38 billion yuan in revenue from U.S. clients, a 28.4% increase, while revenue from Chinese clients decreased by 1.3% [3][4] - Kanglong Chemical's revenue from North American clients was 2.003 billion yuan, up 16.81%, indicating a strong focus on the North American market despite global trade uncertainties [4] Growth Opportunities - The CXO industry is expected to benefit from increased R&D investments and outsourcing penetration, with predictions indicating that by 2030, the scale of drug R&D and production outsourcing services in China could reach 482.3 billion yuan [5][6] - Companies like Kanglong Chemical reported a more than 10% increase in new order amounts in Q1 2025, reflecting a positive trend in order reserves [6] Competitive Landscape - The performance of leading companies is showing significant differentiation, with some like WuXi AppTec experiencing substantial order growth, while others like Tigermed are facing challenges [3][7] - Despite pressures, Tigermed reported a 20% increase in new contract amounts, indicating resilience in securing new business [7] Future Outlook - The CXO sector is transitioning from a focus on cost advantages to a dual barrier of technology and globalization, with companies expected to enhance their positions in the market as they convert order reserves into revenue [8]

Core Insights - The article emphasizes the importance of investment attraction as a key driver for economic development and high-quality growth in Handan Economic Development Zone [1][4] Investment Performance - In 2024, Handan Economic Development Zone successfully signed 38 investment projects with a total investment amount of 32.671 billion yuan, including 5 projects exceeding 1 billion yuan [1] - The number of projects in the reserve and negotiation pipeline has surpassed 100 [1] Industry Focus - The zone is concentrating on four leading industries: high-end equipment manufacturing, high-end white household appliances, new energy, and new materials, aiming to enhance industrial structure and chain [3][4] - Notable signed projects include a 13 billion yuan investment in a new energy electrical steel project and a 3.2 billion yuan investment in a modern cold chain logistics park [3] Infrastructure Development - Handan Economic Development Zone has implemented 73 infrastructure projects with a total investment of 30.963 billion yuan to enhance regional attractiveness [6] New Industry Initiatives - The zone is actively cultivating strategic emerging industries such as digital economy, low-altitude economy, and artificial intelligence, with significant projects like the Handan Digital Economy Industrial Park [7][8] - The digital economy park aims to establish a comprehensive industrial system focusing on information technology, smart hardware, and intelligent manufacturing [7] Service and Support - The zone has established a comprehensive service system to support project implementation, ensuring a friendly investment environment and facilitating project approvals [5][6] - Continuous improvement of service quality has led to positive feedback from businesses regarding the efficiency of project execution [5][8]

前10大未平仓空仓比 智通财经APP获悉，截止5月2日，未平仓空单比位列前三位为药明康德（02359）、万科企业 （02202）、赣锋锂业（01772），空仓比分别为16.40%、14.71%、13.17%。 未平仓空单比（绝对值）较上一次增加最多为万科企业（02202）、中远海控（01919）、耀才证券金融 （01428），分别增加1.37%、0.87%、0.82%。 未平仓空单比（绝对值）较上一次减少最多为赣锋锂业（01772）、地平线机器人-W（09660）、海信 家电（00921），分别减少-0.88%、-0.85%、-0.81%。 未平仓空仓比减少最大的10只股票 | 股票名称 | 上一次空仓比 | 最新空仓比 | | 减少值↓ | | --- | --- | --- | --- | --- | | 赣锋锂业(01772) | 14.05% | 13.17% | -0.88% | | | 地平线机器人-W(09660) | 1.87% | 1.02% | -0.85% | | | 海信家电(00921) | 10.94% | 10.14% | -0.81% | | | 青岛啤酒股份(00168) | ...